Last reviewed · How we verify
Bronchoalveolar lavage fluid collection
Bronchoalveolar lavage fluid collection is a diagnostic sampling procedure that retrieves cellular and fluid samples from the lower respiratory tract for analysis.
Bronchoalveolar lavage fluid collection is a diagnostic sampling procedure that retrieves cellular and fluid samples from the lower respiratory tract for analysis. Used for Diagnosis of pulmonary infections (bacterial, fungal, viral), Evaluation of interstitial lung disease, Investigation of unexplained pulmonary infiltrates.
At a glance
| Generic name | Bronchoalveolar lavage fluid collection |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Biologic |
| Therapeutic area | Pulmonology/Respiratory |
| Phase | Phase 2 |
Mechanism of action
This is a clinical procedure rather than a pharmacological drug. It involves instilling sterile saline into the lungs via bronchoscopy and then aspirating the fluid back to obtain samples of cells, proteins, and pathogens from the alveolar space. The collected fluid is analyzed to diagnose infections, malignancies, inflammatory conditions, and other pulmonary pathologies.
Approved indications
- Diagnosis of pulmonary infections (bacterial, fungal, viral)
- Evaluation of interstitial lung disease
- Investigation of unexplained pulmonary infiltrates
- Assessment of immunocompromised patients with respiratory symptoms
Common side effects
- Transient hypoxemia
- Cough
- Bronchospasm
- Fever
Key clinical trials
- Biobank for the Identification of Biomarkers in Lung Cancer (BIRD, Biomarkers in Respiratory Disease)
- Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
- Effect of tNGS on CAP Patients With Initial Treatment Failure (NA)
- BAL Fluid Biomarkers in Sarcoma (PHASE2)
- The APS Phenotyping Study
- Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
- Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario (PHASE4)
- Mitochondrial Dysfunction of Alveolar and Circulating Immune Cells During Acute Respiratory Distress Syndrome: Impact of Infectious Aggression and Alveolar Stretching as a Result of Mechanical Ventilation.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: